⚠️FOR RESEARCH PURPOSES ONLY
← Back to Research Database
ResearchPeptide

PNC-27

Published Research

PubMed-indexed studies for PNC-27

Research

Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.

Annals of clinical and laboratory science 2024
View on PubMed →
Research

PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.

Biomedicines 2022
View on PubMed →
Research

The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.

Cancer chemotherapy and pharmacology 2010
View on PubMed →
Research

Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.

Annals of clinical and laboratory science 2017
View on PubMed →
Research

The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.

Annals of clinical and laboratory science 2014
View on PubMed →
Research

Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.

Proceedings of the National Academy of Sciences of the United States of America 2010
View on PubMed →

Research-Grade PNC-27

YPB.275
PNC-27 (10mg)
$80.00
⚠️ For laboratory research only. Not for human use.